Date: 14th May 2026

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 531569

Sub: Press Release on Un-audited Financial Results (Standalone and Consolidated) for the First Quarter ended June 30, 2026.

Dear Sir/ Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release on the Un-audited Financial Results (Standalone and Consolidated) for the First Quarter ended June 30, 2026.

Kindly take the above information on your records.

Thanking You,
Yours Faithfully,

For Sanjivani Paranteral Limited

RAVIKUMAR VENKATRAMALU BOGHAM

Digitally signed by RAVIKUMAR VENKATRAMALU BOGHAM
Date: 2026.08.14 16:14:33 +05'30'

Ravikumar Bogam
Company Secretary Cum Compliance Officer

Sanjivani Parenteral Limited Reports Q1 FY27 Results; EBITDA stood at ₹ 43.21 Mn with PAT at ₹ 24.91 Mn

Mumbai, 14th August, 2026: Sanjivani Paranteral Limited (Sanjivani, The Company) (BSE: 531569), one of the emerging players in the pharmaceutical and healthcare manufacturing sector, continued to strengthen its operational performance during the year through improved efficiencies, focused execution, and a customer-centric approach across its business segments, and has announced its Unaudited Financial Results for Q1 FY27.

Key Consolidated Financial Highlights

Particulars (₹ Mn)	Q1 FY27	Q1 FY26	YoY
Total Income	239.90	179.28	⬆ 33.81%
EBITDA	43.21	26.83	⬆ 61.04%
EBITDA Margin (%)	18.01%	14.97%	⬆ 305 Bps
PAT	24.91	17.31	⬆ 43.94%
PAT Margin (%)	10.38%	9.65%	⬆ 73 Bps
EPS (₹)	2.03	1.41	⬆ 43.97%

Segment-wise Performance:

- Injectables: Revenue stood at ₹110.12 Mn, contributing 56.59% of revenue from operations, YoY growth of 22.54%
- Tablets: Revenue stood at ₹84.28 Mn, contributing 43.32% of revenue from operations
- Nutraceuticals: Revenue stood at ₹0.18 Mn, accounting for 0.09% of revenue from operations

Market-wise Performance:

- Exports (incl. incentives): Contributed 90.50% of revenue from operations (₹176.10 Mn), YoY growth of 33.49%, while domestic accounted for 9.50% (₹18.49 Mn)
- Core markets (Latin America, CIS, Middle East & Africa): Contributed 90.50% of revenue from operations, amounting to ₹176.10 Mn, YoY growth of 33.49%

Commenting on the performance, Mr. Ashwani Khemka, Chairman & Managing Director of Sanjivani Paranteral Limited said, "Q1 FY27 was marked by a positive start for Sanjivani Parenteral, supported by a recovery in exports and continued operational focus. The Pune IV Fluid facility is witnessing a gradual scale-up, with increasing commercialization and customer traction, while our core formulations business remains resilient.

These operational developments were complemented by healthy financial performance during the quarter. Total Income registered a 33.81% YoY growth, while EBITDA increased 61.04% YoY, with EBITDA margin improving by 305 Bps to 18.01%, reflecting improved operating efficiencies and stronger business performance. Net Profit grew 43.94% YoY during the quarter, with PAT margin improving to 10.38%.

Going forward, we remain focused on strengthening our manufacturing capabilities, expanding our product portfolio and enhancing our presence across domestic and international markets. We will continue to leverage improving operational efficiencies, growing customer traction and market opportunities to drive sustainable growth and create long-term value for our stakeholders."

About Sanjivani Paranteral Limited

Sanjivani Parenteral Limited (BSE: 531569) is engaged in the pharmaceutical and healthcare manufacturing business, with a focus on delivering quality products and maintaining strong operational standards. The Company continues to strengthen its presence through operational excellence, customer-centric execution, and continuous focus on quality and compliance.

With a commitment towards sustainable growth and long-term value creation, the Company continues to focus on enhancing manufacturing capabilities, improving efficiencies, and expanding its business presence across key markets.

For FY26, the company has reported Total Income of ₹ 697.56 Mn, EBITDA of ₹ 114.00 Mn & PAT of ₹ 66.94 Mn on consolidated basis.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact

Kirin Advisors	**Kirin Advisors Private Limited** Sunil Mudgal – Director sunil@kirinadvisors.com +91 98692 75849 www.kirinadvisors.com